Dyne Therapeutics (DYN) Competitors

Dyne Therapeutics logo
$16.70 -0.46 (-2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$16.70 0.00 (0.00%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DYN vs. SMMT, KYMR, BMRN, PCVX, and IBRX

Should you buy Dyne Therapeutics stock or one of its competitors? Dyne Therapeutics's main competitors and comparable companies include Summit Therapeutics (SMMT), Kymera Therapeutics (KYMR), BioMarin Pharmaceutical (BMRN), Vaxcyte (PCVX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyne Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Summit Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A

Summit Therapeutics has a beta of -1.49, indicating that its stock price is 249% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 81.8% of Summit Therapeutics shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dyne Therapeutics' return on equity of -69.73% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -138.82% -117.11%
Dyne Therapeutics N/A -69.73%-53.82%

Summit Therapeutics presently has a consensus price target of $28.61, suggesting a potential upside of 102.17%. Dyne Therapeutics has a consensus price target of $31.29, suggesting a potential upside of 82.32%. Given Summit Therapeutics' higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69

In the previous week, Dyne Therapeutics had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 13 mentions for Dyne Therapeutics and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Dyne Therapeutics' score of 0.18 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Dyne Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Dyne Therapeutics beats Summit Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Dyne Therapeutics compare to Kymera Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Dyne Therapeutics currently has a consensus target price of $31.29, indicating a potential upside of 82.32%. Kymera Therapeutics has a consensus target price of $139.16, indicating a potential upside of 9.09%. Given Dyne Therapeutics' higher probable upside, research analysts clearly believe Dyne Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

Dyne Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Dyne Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -22.39% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -69.73% -53.82%
Kymera Therapeutics -285.33%-22.39%-20.48%

In the previous week, Dyne Therapeutics had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for Dyne Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Dyne Therapeutics' score of 0.18 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.7% of Dyne Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics has higher revenue and earnings than Dyne Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A

Summary

Kymera Therapeutics beats Dyne Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Dyne Therapeutics (NASDAQ:DYN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics currently has a consensus price target of $31.29, indicating a potential upside of 82.32%. BioMarin Pharmaceutical has a consensus price target of $87.22, indicating a potential upside of 52.40%. Given Dyne Therapeutics' higher possible upside, research analysts clearly believe Dyne Therapeutics is more favorable than BioMarin Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

BioMarin Pharmaceutical has higher revenue and earnings than Dyne Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A
BioMarin Pharmaceutical$3.22B3.44$348.90M-$0.10N/A

Dyne Therapeutics has a net margin of 0.00% compared to BioMarin Pharmaceutical's net margin of -0.52%. BioMarin Pharmaceutical's return on equity of 5.58% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -69.73% -53.82%
BioMarin Pharmaceutical -0.52%5.58%3.51%

In the previous week, Dyne Therapeutics had 4 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 13 mentions for Dyne Therapeutics and 9 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.35 beat Dyne Therapeutics' score of 0.18 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioMarin Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dyne Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Summary

BioMarin Pharmaceutical beats Dyne Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Vaxcyte?

Dyne Therapeutics (NASDAQ:DYN) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics currently has a consensus price target of $31.29, indicating a potential upside of 82.32%. Vaxcyte has a consensus price target of $110.50, indicating a potential upside of 74.37%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dyne Therapeutics is more favorable than Vaxcyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Vaxcyte is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A
VaxcyteN/AN/A-$766.63M-$8.06N/A

Vaxcyte's return on equity of -42.04% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -69.73% -53.82%
Vaxcyte N/A -42.04%-36.82%

In the previous week, Dyne Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 13 mentions for Dyne Therapeutics and 12 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.88 beat Dyne Therapeutics' score of 0.18 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dyne Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Summary

Dyne Therapeutics beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

How does Dyne Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Dyne Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -607.79%. ImmunityBio's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-607.79% N/A -54.83%
Dyne Therapeutics N/A -69.73%-53.82%

In the previous week, ImmunityBio had 23 more articles in the media than Dyne Therapeutics. MarketBeat recorded 36 mentions for ImmunityBio and 13 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.18 beat ImmunityBio's score of -0.18 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral
Dyne Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

ImmunityBio has higher revenue and earnings than Dyne Therapeutics. ImmunityBio is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M56.53-$351.40M-$1.08N/A
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

ImmunityBio currently has a consensus price target of $16.00, suggesting a potential upside of 165.78%. Dyne Therapeutics has a consensus price target of $31.29, suggesting a potential upside of 82.32%. Given ImmunityBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImmunityBio is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69

Summary

ImmunityBio and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DYN vs. The Competition

MetricDyne TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.13B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-4.6024.2434.3430.11
Price / SalesN/A14.858.005.32
Price / CashN/A21.8921.0222.34
Price / Book2.454.354.763.85
Net Income-$446.21M-$24.19M$3.52B$393.14M
7 Day Performance-10.31%-7.26%-5.34%-4.53%
1 Month Performance17.19%-4.96%-3.61%-5.86%
1 Year Performance-11.12%-2.87%0.01%-7.78%

Dyne Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DYN
Dyne Therapeutics
3.2798 of 5 stars
$16.70
-2.7%
$31.29
+87.3%
-8.7%$3.13BN/AN/A258
SMMT
Summit Therapeutics
2.6535 of 5 stars
$17.84
+9.2%
$28.61
+60.4%
-21.5%$12.93BN/AN/A265
KYMR
Kymera Therapeutics
2.1601 of 5 stars
$138.86
+5.4%
$139.16
+0.2%
+96.4%$11.63B$39.21MN/A285
BMRN
BioMarin Pharmaceutical
4.1822 of 5 stars
$57.18
+2.1%
$87.91
+53.7%
+4.6%$11.07B$3.22B32.103,221
PCVX
Vaxcyte
3.0912 of 5 stars
$67.53
+5.7%
$110.50
+63.6%
+30.1%$9.77BN/AN/A507

Related Companies and Tools


This page (NASDAQ:DYN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners